PwPepwise

Vilon

Anti-Aging & Longevity

Khavinson dipeptide (Lys-Glu)

Vilon is a synthetic dipeptide composed of two amino acids — lysine and glutamic acid (Lys-Glu).

§Dosing at a glance

1 protocol · from the research
What it's forDoseHow oftenHowFor how long
Animal studies (mouse/rat)10 ngOnce dailySubcutaneousInjected just under the skin, into the fat layer.6 mos

Approximate values pulled from the research — double-check before dosing.

§01Summary

Vilon is a synthetic dipeptide composed of two amino acids — lysine and glutamic acid (Lys-Glu) — originally derived from thymic peptide complexes called cytomedins. It belongs to a class of short bioregulatory peptides developed in Russia, designed to mimic the signaling activity of natural thymic hormones that help regulate immune function, aging, and tissue homeostasis.

In preclinical research, Vilon has been reported to stimulate thymic immune cell development and T-helper cell differentiation6, support post-radiation recovery of immune and intestinal tissues17, and demonstrate age-compensatory effects on digestive enzyme activity9 and chromatin remodeling in aged cells4. In a human study, Vilon may reduce markers of abnormal blood clotting in type 1 diabetes patients1. Preliminary animal evidence also suggests potential geroprotective effects, including increased physical activity and reduced spontaneous tumor incidence in mice8, as well as reduced chemically induced bladder tumor incidence in rats12,19. However, Vilon has also been reported to increase mammary tumor development in a specific transgenic mouse model overexpressing HER-2/neu2,14, a finding that has shaped important questions in its ongoing research. Human studies are emerging across several indications, and the evidence base for Vilon continues to develop.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Vilon (L-Lys-L-Glu) is a synthetic dipeptide analog derived from thymic cytomedin complexes — high-molecular-weight peptide fractions originally extracted from thymic tissue. As a thymomimetic compound, it was designed to replicate the bioregulatory signaling activity of endogenous thymic hormones involved in immune system development and homeostasis.

At the cellular signaling level, Vilon has been reported to stimulate thymocyte blast transformation and modulate comitogenic activity of interleukin-1β, with the sphingomyelin signal transduction pathway identified as a likely mechanistic intermediary10. Specifically, Vilon produces pronounced stimulatory effects on sphingomyelinase activity in thymocyte membranes, suggesting engagement of ceramide-dependent intracellular signaling cascades. In thymic cell culture models, Vilon promotes the differentiation of CD5+ T-cell precursors toward CD4+ T-helper lineages6, and in aging spleen tissue, it appears to exert anti-apoptotic effects selectively on T-helper cell populations20.

Vilon demonstrates tissue-specific activity consistent with its thymic origin: in organotypic culture models, it preferentially stimulates growth of thymic explants over tissues of other organ origins11, supporting the concept of organ-derived peptide cytogens retaining tissue-selective biological information. At the epigenetic level, Vilon has been reported to induce deheterochromatinization of facultative heterochromatin in lymphocytes from aged individuals — selectively decondensing age-accumulated chromatin silencing without disrupting pericentromeric structural heterochromatin — with corresponding reactivation of nucleolar organizer regions and ribosomal gene expression4.

Vilon's effects on oxidative biology appear compartment-specific: in Drosophila melanogaster subcellular fractions, it was reported to inhibit reactive oxygen species generation in mitochondria while simultaneously stimulating ROS production in the cytosol5, suggesting organelle-selective modulation rather than simple antioxidant or pro-oxidant activity. In cardiac tissue, Vilon altered the expression of 36 gene clones (out of 15,247 screened), with combined Vilon and Epitalon treatment producing broader transcriptional effects (144 clones affected), indicating potential for additive genomic interactions3. On innate immunity, Vilon has been reported to upregulate IL-1β and iNOS mRNA expression and enhance secretion of IL-1β and nitric oxide from LPS-activated peritoneal macrophages in a dose-dependent manner16, consistent with immunostimulatory rather than immunosuppressive activity in the innate compartment. Formal pharmacokinetic parameters — including half-life, bioavailability, and metabolic fate — have not been characterized in the reviewed literature and represent an active area of investigation.

§04Evidence & efficacy

Evidence base
66Studies
8Human
30Animal

Vilon has been investigated across several biological domains, with the most substantive human evidence coming from a single randomized study in type 1 diabetes.

Coagulation and diabetes: In type 1 diabetes patients experiencing destabilization, Vilon may significantly reduce markers of chronic disseminated intravascular coagulation (DIC), including improvements in coagulability, antithrombin III, protein C, fibrinogen, and fibrinolytic activity, while standard diabetes treatment alone showed no significant effect on these parameters1. Response appeared age- and severity-dependent, with reduced efficacy in elderly patients with advanced disease1.

Immunomodulation: Vilon has been reported to promote CD4+ T-helper cell differentiation from T-cell precursors in thymic cell cultures derived from both human and animal tissue6, and may reduce T-helper cell apoptosis in aging spleen20. It appears to stimulate thymocyte proliferation and exhibit comitogenic activity via the sphingomyelin signaling pathway10.

Geroprotection: In animal models, Vilon has been reported to increase physical activity, reduce body temperature, extend lifespan, and reduce spontaneous neoplasm incidence in female CBA mice8. Preliminary evidence suggests age-compensatory improvements in digestive enzyme activity in older rats9 and enhanced intestinal nutrient absorption in aged animals18.

Oncology — mixed signals: Vilon appears to inhibit chemically induced urinary bladder carcinogenesis in rats, reducing tumor incidence from approximately 75.5% to 56%12,19. However, in HER-2/neu transgenic mice, Vilon was associated with increased mammary tumor incidence and accelerated tumor onset compared to saline controls2,14.

Radioprotection and stress: Vilon has been reported to stimulate thymocyte and intestinal stem cell proliferation following gamma-irradiation17, and may attenuate stress-induced immunosuppression and adrenal hypertrophy in rats13,15.

§05Safety

Vilon's safety profile is characterized by limited human tolerability data and a mixed signal from animal oncology models.

In a long-term mouse study, chronic subcutaneous administration of Vilon was reported to cause no unfavorable effects on animal development, suggesting acceptable tolerability at the doses tested8. In rat models, no explicit adverse events were reported across studies examining digestive, immune, stress-protective, and intestinal transport endpoints9,13,18.

A notable finding across multiple animal oncology studies is that Vilon was associated with increased mammary tumor incidence, shorter tumor latency, and higher cumulative tumor burden compared to saline controls in HER-2/neu transgenic mice2. A separate study in the same transgenic model reported that the proportion of mice developing multiple tumors was higher in the Vilon group (95%) compared to controls (75%), and a 2.6-fold higher lung metastasis incidence was observed relative to the Epitalon-treated group14. These pro-tumorigenic signals in an oncogene-overexpression model represent observed biological findings in preclinical research.

Vilon has also been reported to enhance LPS-activated macrophage secretion of IL-1β and nitric oxide in a dose-dependent manner16, indicating immunostimulatory activity on innate immune cells that may be relevant in inflammatory contexts.

No drug interactions, contraindications, or human adverse event data were reported in the studies reviewed1,6.

§06History

Vilon (Lys-Glu) was developed within the Russian bioregulatory peptide research program initiated in the 1970s–1980s by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. This program sought to identify the minimal active peptide sequences responsible for the organ-specific biological activity of cytomedin complexes — high-molecular-weight polypeptide fractions isolated from various tissues. Vilon was derived from thymic cytomedins as a synthetic dipeptide intended to replicate thymic hormonal signaling relevant to immune regulation and aging.

Early research in the late 1990s and early 2000s established Vilon's thymomimetic activity in animal models, with studies demonstrating tissue-specific organotypic stimulation11, effects on thymocyte proliferation and sphingomyelin signaling10, and geroprotective outcomes including lifespan extension in mice8. A 2001–2002 period of peak publication activity explored its roles in digestive function9, radioprotection17, intestinal absorption18, and oncology, with contrasting findings in bladder carcinogenesis12,19 versus mammary tumor models2,14. Cardiac gene expression profiling using DNA microarray technology was conducted in 2002, positioning Vilon in a genomics-era mechanistic framework3.

Human research includes a 2006 randomized study in type 1 diabetes patients examining coagulation effects1 and chromatin remodeling studies in aged lymphocytes4. Vilon has not received regulatory approval in Western markets; it is studied primarily within Russian and Eastern European biogerontology research networks. The evidence base for Vilon continues to develop, with ongoing interest in its immunomodulatory and geroprotective properties.

§07References